Screening and prevention strategies for breast cancer (BC) have focused on women over 40 years of age. While BC prevalence under 40 is low, affected patients have more aggressive cancers and a poorer prognosis. Those with identifiable risk factors may benefit from screening for early detection and prevention strategies. This paper reviews the current literature and guidelines regarding BC risk. Screening guidelines and prevention strategies are also reviewed, with a focus on females under the age of 40.
Cancer Stat Facts: Common Cancer Sites. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. [Online]. AccessedMarch 12, 2025https://seer.cancer.gov/statfacts/html/common.html
2.
KatoakaAIwamotoTTokunagaE, et al.Young adult breast cancer patient have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanesse breast cancer Registry. Breast Cancer Res, Treat. 2016;160:163-172.
3.
ShimonPaluch-PaganiOPartridgeAH, et al.ESO=ESMO 3rd international consensus guidelines for breast cancer in youg women (BCY3). Breast. 2017;35:203-217.
United States Cancer Statistics: Data Visualizations. Cancers by Age, Sex, Race and Ethnicity. CDC. [Online]June2024. AccessedAugust 24, 2024. https://gis.cdc.gov/Cancer/USCS/#/Demographics/
6.
XuSMurtaghSHanYWanFToriolaA. Breast cancer incidence among US women aged 20 to 49 years by race, stage, and Hormone receptor status. JAMA Netw Open. 2024;7(1):e2353331.
7.
ZhuJWCharkhchiPAdekunteSAkbariM. What is known about breast cancer in young women. Cancers. 2023;15(6):1917.
8.
GathaniTReevesGBroggioJBarnesI. Ethnicity and the tumour characteristics of invasive breast cancer in over 116,500 women in England. Br J Cancer. 2021;125:611-617.
9.
OeffinigerKCFonthamETEtzioniR, et al.Breast cancer screening for women at average risk: 2015 guideline update from the American cancer society. JAMA. 2015;314:1599.
10.
PartridgeAHughesMWarnerE, et al.Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34(27):3308.
11.
MonticcioloDNewellMMoyLLeeCDestounisS. Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR. J Am Coll Radiol. 2023;20(9):902-914.
MulderRLHudsonMMBhatiaS, et al.Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent and young adult care from the international guideline hamonization group. J Clin Oncol. 2020;38:4194-4207.
14.
RaczJMCarterJMDegnimAC. Lobular neoplasia and atypical ductal hyperplasia on core biopsy: current surgical management recommendations. Ann Surg Oncol. 2017;24:2848-2854.
ClausEBSchildkrautJMThompsonWBRischNJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
17.
DeSantisCEMaJGodingSANewmanLAJemalA. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67:439-448.
18.
AmirikiaKCMillsPBushJNewmanLA. Higher-population-based incidence rates of triple-negative breast cancer among young African-American women. Cancer. 2011;117:2747-2753.
19.
HendrickREHelvieMA. United States preventative Services Task Force screening mammography recommendations: science ignored. AJR Am J Roentgenol. 2011;196:W112.
20.
SiddigATengku DinTADANafiSNMYahyaMMSulongSRahmanWFWA. The unique biology behind the early onset of breast cancer. Genes (BASEL). 2021;12:372.
21.
KingMWieandSHaleK, et al.Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251-2256.
22.
KauffNDPerez-SeguraPRobsonME, et al.Incidence of non-founder BRCA1 and BRCA2 mutations in high-risk Ashkenazi breast and ovarian cancer families. J Med Genet. 2002;39(8):611.
23.
CoxDMNelsonKLClytoneMCollinsDL. Hereditary cancer screening: case reports and review of literature on ten Ashkenazi jewish founder mutations. Mol Genet Genomic Med. 2018;6(6):1236.
24.
ChurpekJEWalshTZhengY, et al.Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2014;149:31-39.
25.
Genetic/Familial High-Risk Assessment, and Pancreatic. National Comprehensive Cancer Network. [Online] March 6, 2025. AccessedApril 8, 2025genetics_bopp.pdf.
26.
American CancerSociety.Breast Cancer Facts and Figures 2009-2010. Atlanta: American Cancer Society Inc; 2009.
27.
MonticcioloDLNewellMSMoyLLeeCSDestounisSV. Breast cancer screening for women at higher-than-average-risk: updated recommendations from ACR. J Am Coll Radiology. 2023;20:902-914.
28.
KimGManishaB. Assessing risk of breast cancer: a review of risk prediction models. J Breast Imaging. 2001;3(2):144-155.
29.
BrentnallACuzickJBuistDAiello BowlesEJ. Long-term accuracy of breast cancer risk assessment combining classic risk factors and breast density. JAMA Oncol. 2018;4:e180174.
PijpeAAndrieuNEastonDF. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA 1/2 mutations: a retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660.
32.
MonticcioloDLMalakSFFriedewaldSM, et al.Breast cancer screening recommendations inclusive of all women at average risk: update from ACR and society of breast imaging. J Am Coll Radiol. 2021;18:1280-1288.
33.
MarinovichMLHunterKEMacaskillPHoussamiN. Breast cancer screening using tomosynthesis or mammography: a meta-analysis of cancer detection and recall. J Natl Cancer Inst. 2018;110:942-949.
34.
BahlMMercaldoSMcCarthyAMLehmanCD. Imaging surveillance of breast cancer survivors with digital mammography versus digital breast tomosynthesis. Radiology. 2021;298:309-316.
35.
ChikarmaneSACochonLRKhorasaniRSahuSGiessCS. Screening mammography performance metrics of 2D mammography versus digital breast tomosynthesis in women with a personal history of breast cancer. AJR Am J Roentgenol. 2021;217:587-594.
36.
ChiarelliAMBlackmoreKMMuradaliD, et al.Performance measures of magnetic resonance imaging plus mammography in the high-risk Ontario breast screening program. J Natl Cancer Inst. 2020;112:136-144.
37.
LowryKPGeuzingeHAStoutNK, et al.Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis. JAMA Oncol. 2022;8:587-596.
38.
KuhlCKStrobelKBielingHLeutnerCSchildHHSchradingS. Supplemental breast MR imaging screening of women with average risk of breast cancer. Radiology. 2017;283:361-370.
39.
BuchbergerWGeiger-GritschSKnappRGautschKOberaignerW. Combined screening with mammogram and ultrasound in a population-based screening program. Eur J Radiology. 2018;101:24-49.
40.
McCormackVAdos Santos SilvaI. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:1159.
41.
OhuchiNSuzukiASobueT, et al.Sensitivity and specificity of mammography and adjunctive ultrasounography to screen for breast cancer in the Japan strategic anti-cancer randomized trial (J-START): a randomized controlled trial. Lancet. 2016;387:341-348.
42.
WangLStrigelRM. Supplemental screening for patients at intermediate risk and high risk for breast cancer. Radiol Clin North Am. 2021;59:67-83.
43.
KaminskyOHalimNAZilbermintsVSharonEAranovichD. Young woman in the breast clinic: ultrasound or not?J Clin Oncology. 2019;37(19):1629-1637.
VogelVGCostantinoJPWickerhamDL, et al.Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res. 2010;3:696-706.
47.
DeCensiAPuntoniMGuerrieri-GonzagaA, et al.Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37(19):1629-1637.
48.
LazzeroniMPuntoniMGuerrieri-GonzagaA, et al.Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study. J Clin Oncol. 2023;41(17):3116-3121.
The American College of Obstetricians and Gynecologists. Breast Cancer Risk Assessment and Screening in Average-Risk Women. Practice Bulletin. 179.(July 2017) 2019-1.
